<DOC>
	<DOCNO>NCT01315639</DOCNO>
	<brief_summary>The aim study examine relationship plasma putative biomarkers Alzheimer 's disease ( i.e . Ab40 amyloid total Ab42 amyloid , free , bound , free/bound , truncate , sAPPα ) : - risk conversion individual Mild Cognitive Impairment ( MCI ) Alzheimer 's disease ( AD ) , - Alzheimer 's disease progression rate .</brief_summary>
	<brief_title>New Biomarker Alzheimer 's Disease Diagnostic</brief_title>
	<detailed_description>Rational Whether biological marker Alzheimer 's disease ( AD ) crucial adequate target appropriate management disease . The aim study examine diagnostic performance predictive prognostic value new plasma marker AD . Results study predictive value plasma concentration Aβ40 42 amyloid peptide incident AD straightforward . Discrepancies result may due fact total peptide concentration measure . One recent study suggest plasma free Aβ peptide concentration particularly low-density lipoprotein receptor-related protein ( LPR ) like free Aβ/total Aβ ratio would reliable discriminant . Main objective study To examine association plasma free Aβ peptide concentration ( 1 ) risk conversion subject Mild Cognitive Impairment ( MCI ) Alzheimer 's disease ( AD ) ( 2 ) risk worsen disease patient mild moderate stage AD . Secondary objectives - To examine association total peptid Aβ concentration , free Aβ/Total Aβ ratio , trunked plasmatic Aβ risk incident AD MCI subject , risk worsen disease mild moderate AD patient , - To examine association serum sAPP concentration risk incident AD MCI subject , risk worsen disease mild moderate AD patient , - To compare time evolution concentration biomarkers Alzheimer 's disease progression rate assess basis neuropsychological examination MRI examination hippocampal atrophy , - To examine association serum cerebrospinal fluid ( CSF ) concentration AD biomarkers subgroup participant undergo lumbar puncture , - To examine association neuroimaging data ( cerebral volume , hippocampal volume , cerebrovascular lesion plasma CSF AD biomarkers ' concentration , - To constitute blood plasma bank , gene bank CSF bank future study biomarkers AD . Design Methods Longitudinal multicenter study include 1300 subject amnestic impairment ( MCI , n=650 AD , n=650 ) derive main French national Memory Resources Research Centers . Participants undergo baseline every 6 month neurological examination , neuropsychological assessment ( oculomotor examination include Broca Hospital ) . Alzheimer disease biomarkers ' measurement perform inclusion end study . For MCI participant convert dementia , end study correspond AD conversion period . A Magnetic Resonance Imaging ( MRI ) scan perform inclusion end study MCI subject convert AD . A lumbar puncture outpatient basis perform study entry participant give inform consent examination absence contraindication .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>MCI group : ≥ 70 year MCI diagnosis : New criterion ( Petersen , PORTET* ) 1. cognitive complaint patient , family , , 2. report subject reporter decline cognitive functional performance , relative previous ability , 3. cognitive disorder evidence clinical evaluation : impairment memory another cognitive domain , 4. cognitive impairment without repercussion daily life , even subject report difficulty concern complex daily activity , 5. dementia Having sign informed consent form Fluent French AD group : ≥ 45 year AD diagnosis ( DSM IVTR et NINCDSADRDA ) Mild moderate ( MMSE &gt; 15 ) Having sign informed consent form Caregiver/informant provide information patient Normal cognitive function Major depression ( accord DSMIVTR MINI Geriatric depression Scale &gt; 20/30 ) Genetic form AD ( genetic mutation know ) All disease could interfere cognitive assessment ( Epilepsy , Parkinson 's disease , schizophrenia , dementia ) Major sensory deficit could interfere cognitive assessment ( visual auditory ) Diseases involve shortterm survival ( advanced cancer , unstable heart disease , severe hepatic/respiratory/renal failure ) Contraindication MRI , lumbar puncture ( i.e . anticoagulant agent ) Use experimental agent duration study Participation biomedical research could interfere principal objective study For MCI patient , use IchE memantine medication inclusion Less 4 year education Illiteracy , unable count read Pregnant woman Non health insurance affiliation Private subject freedom legal administrative decision Contraindication MRI examination : Claustrophobic subject Carrying cardiac pacemaker Presence ferromagnetic metallic implant foreign body ( carry internal electrical/magnetic device , carry valvular prosthesis ) Carrying ventricular valvular Exclusion criterion specific lumbar puncture : • Taking anticoagulant agent</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Dementia</keyword>
	<keyword>Cognitive impairment</keyword>
	<keyword>Memory impairment</keyword>
	<keyword>Mild Cognitive Impairment</keyword>
	<keyword>Cerebrospinal fluid</keyword>
	<keyword>Plasma</keyword>
	<keyword>Biomarker</keyword>
	<keyword>Longitudinal</keyword>
	<keyword>Abeta peptide amyloid , saPP alpha</keyword>
	<keyword>Oculomotor impairment</keyword>
</DOC>